Testing venetoclax with chemo and midostaurin for FLT3-mutated AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs — venetoclax, standard chemotherapy (3+7), and midostaurin — for people with newly diagnosed AML that has a FLT3 mutation. The goal is to see if adding venetoclax improves the effectiveness of the standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old.
- You must have been recently diagnosed with AML that has a FLT3 gene mutation.
- Your heart must be working well (checked by an EKG and an ultrasound test).
- You must not have taken any treatment for your AML yet, except for supportive care.
- You must not have been treated with venetoclax before.
- Your AML must not be caused by a previous blood disorder or previous cancer treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.